Lytix Biopharma’s LTX-315 Receives EC’s Approval to Initiate P-II (ATLAS-IT-05) Study for Advanced Melanoma in EU
Shots:
- The EC has granted approval to initiate the P-II (ATLAS-IT-05) study in 3 EU countries to evaluate LTX-315 + pembrolizumab for advanced melanoma. The study is currently ongoing in the US, initiated in 2021 at MD Anderson Cancer Center. Patients’ enrolment is ongoing & is expected to be completed in early 2023
- The study purposes are to determine the effectiveness of LTX-315 + pembrolizumab in inducing responses for patients who have failed prior anti-PD 1/PD L1 immune checkpoint therapy
- In 3 EU countries, the study will take place at highly recognized sites with intratumoral immunotherapy experience. The same procedures as in the US will be followed, and each site will be overseen by melanoma experts
Ref: PR Newswire | Image: Lytix
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
